Ep. 116: “Allelic Variation” Featuring Dr. Robin Orozco
Dr. Robin Orozco is an Assistant Professor at the University of Kansas, where her lab studies how specific allelic variants affect immune responses. She talks about what we can learn from mouse models and the role of PTPN22 in antiviral immunity.
--------
1:10:58
--------
1:10:58
Ep. 115: “Intercellular Communication” Featuring Dr. Harikesh Wong
Dr. Harikesh Wong is an Assistant Professor at the Ragon Institute and MIT, where his lab studies the design principles of the immune system. He talks about how Tregs constrain conventional T cell responses during infection, and advanced fluorescence microscopy techniques to study immune responses.
--------
1:11:26
--------
1:11:26
Ep. 114: “The Importance of Investing in Science” Featuring Dr. Eric Vivier
Dr. Eric Vivier is a Professor of Immunology at Aix-Marseille Université and the Centre d'Immunologie de Marseille-Luminy. He is also an awardee of the European Research Council and a member of the French Society of Immunology. In this special episode recorded at the IUIS 2025 Congress in Vienna, Dr. Vivier highlights the critical importance of investing in science, explores the responsibility of governments and other organizations in funding research, and reflects on the role science plays in society.
--------
1:09:35
--------
1:09:35
IUIS 2025: On the Ground
In August 2025, we attended the 19th International Congress of Immunology, hosted by the International Union of Immunological Societies, in Vienna, Austria. We chat with delegates about their research and impressions of the meeting. They discuss the most memorable research presented and their experiences in Austria.
--------
54:33
--------
54:33
Ep. 112: “The Evolution of mRNA-Based Dendritic Cell Cancer Vaccines” Featuring Dr. Zwi Berneman
Dr. Zwi Berneman is Emeritus Professor of Hematology at the University of Antwerp, and previously Head of the Division of Hematology at the Antwerp University Hospital. His basic and clinical research is focused on vaccination with immunogenic dendritic cells in cancer and with tolerogenic dendritic cells in multiple sclerosis. He talks about the history and development of dendritic cell vaccines and the work needed to make them more widely available to patients.
Österreich